Jennifer Towne

Outlook Microsoft Office 365 Amazon AWS Disqus Apache Greenhouse.io reCAPTCHA Google Analytics BugHerd Vimeo Google Tag Manager Mobile Friendly Remote AI

biotechnology: biological products (no diagnostic substances) health care biotechnology research antibody therapy immune system antibody discovery pro-xten technology oncology solutions infectious disease treatments monoclonal antibodies therapeutic antibodies engineered antibodies vaccine development cancer immunotherapy immunological responses half-life optimization toxicity reduction biologic drugs drug delivery systems clinical development ai in medicine protease-releasable masking targeted therapies patient outcomes chronic hepatitis b chronic hepatitis delta covid-19 therapy ebola treatment pharmacokinetics pharmaceutical innovations t-cell engagers precision medicine viral suppression broadly neutralizing antibodies antibody fragments cancer therapies drug candidates therapeutic interventions r&d strategies machine learning in drug discovery biotechnology advancements clinical efficacy safety profiles regulatory approvals pharmaceutical research strategic collaborations biopharmaceuticals clinical trials early-stage drug development patient-centric treatments latency reversal agents biologics commercialization biopharmaceutical clinical-stage immunology infectious diseases oncology antibody-based therapies covid-19 hiv rsv influenza transformative medicines next-generation antibody platform unmet medical needs therapeutic focus global health healthcare providers patient demographics biotechnology collaborations strategic partnerships innovative therapies cancer treatments preclinical pipeline solid tumors antiviral therapies disease prevention public health organizations scientific excellence patient advocacy social responsibility health wellness & fitness hospital & health care